Breast Cancer (Triple Negative Breast Cancer (TNBC))
Oncology·MeSH: Breast Neoplasms
Prevalence
289.8 / 100K
Incidence
30.4 / 100K/yr
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| ivac_w_bre1_uid | BioNTech SE (BNTX) |
Frequently asked questions
How many drugs are in development for Breast Cancer (Triple Negative Breast Cancer (TNBC))?
BioSniper tracks 1 drug in development for Breast Cancer (Triple Negative Breast Cancer (TNBC)) across 1 company.
How many clinical trials target Breast Cancer (Triple Negative Breast Cancer (TNBC))?
There are 2 clinical trials targeting Breast Cancer (Triple Negative Breast Cancer (TNBC)) tracked by BioSniper.
What is the prevalence of Breast Cancer (Triple Negative Breast Cancer (TNBC))?
The estimated prevalence of Breast Cancer (Triple Negative Breast Cancer (TNBC)) is approximately 289.8 per 100,000 population.
Deep-dive into Breast Cancer (Triple Negative Breast Cancer (TNBC))
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis